Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes—cardiovascular and renal benefits in patients with chronic kidney disease

被引：0
|
作者：
Tamara Y. Milder
Sophie L. Stocker
Dorit Samocha-Bonet
Richard O. Day
Jerry R. Greenfield
机构：
[1] St. Vincent’s Hospital,Department of Diabetes and Endocrinology
[2] St. Vincent’s Hospital,Department of Clinical Pharmacology and Toxicology
[3] University of NSW,St. Vincent’s Clinical School
[4] Garvan Institute of Medical Research,Diabetes and Metabolism
来源：
European Journal of Clinical Pharmacology | 2019年 / 75卷
关键词：
SGLT2 inhibitor; Pharmacokinetics; Cardiovascular outcomes; Efficacy; Safety; Chronic kidney disease;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1481 / 1490
页数：9
相关论文
共 50 条
  • [31] Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Non-Diabetic Chronic Kidney Disease
    Mima, Akira
    ADVANCES IN THERAPY, 2021, 38 (05) : 2201 - 2212
  • [32] Cardiovascular Effects of Sodium-Glucose Cotransporter-2 Inhibitors in Adults With Type 2 Diabetes
    Woo, Vincent C.
    CANADIAN JOURNAL OF DIABETES, 2020, 44 (01) : 61 - 67
  • [33] Do the benefits of sodium-glucose cotransporter 2 inhibitors exceed the risks in patients with type 1 diabetes?
    Kamoshima, Hikaru
    Nomoto, Hiroshi
    Yamashita, Kumiko
    Takahashi, Yuka
    Tsuchida, Kazuhisa
    Kuwabara, Saki
    Miya, Aika
    Cho, Kyu Yong
    Kameda, Hiraku
    Nakamura, Akinobu
    Atsumi, Tatsuya
    Taneda, Shinji
    Kurihara, Yoshio
    Aoki, Shin
    Ono, Yuri
    Miyoshi, Hideaki
    ENDOCRINE JOURNAL, 2021, : 495 - 509
  • [34] Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Retinopathy in Patients With Type 2 Diabetes
    Yen, Fu-Shun
    Wei, James Cheng-Chung
    Yu, Teng-Shun
    Hung, Yu-Tung
    Hsu, Chih-Cheng
    Hwu, Chii-Min
    JAMA NETWORK OPEN, 2023, 6 (12) : E2348431
  • [35] Initial dip predicts renal protective effects after the administration of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes and chronic kidney disease with normoalbuminuria
    Takahashi, Kiyohiko
    Nakamura, Akinobu
    Furusawa, Sho
    Yokozeki, Kei
    Sugawara, Hajime
    Yanagisawa, Hideyuki
    Akikawa, Kazumasa
    Kikuchi, Hideaki
    JOURNAL OF CLINICAL AND TRANSLATIONAL ENDOCRINOLOGY, 2020, 22
  • [36] Sodium-Glucose Cotransporter 2 Inhibitors and Nephrolithiasis Risk in Patients With Type 2 Diabetes
    Paik, Julie M.
    Tesfaye, Helen
    Curhan, Gary C.
    Zakoul, Heidi
    Wexler, Deborah J.
    Patorno, Elisabetta
    JAMA INTERNAL MEDICINE, 2024, 184 (03) : 265 - 274
  • [37] Effect of cardiovascular disease and diuretic use on amputation risk with sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes
    Park, Sohee
    Jeong, Han Eol
    Bea, Sungho
    Yu, Oriana Hoi Yun
    Shin, Ju-Young
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 270 - 270
  • [38] Effect of sodium-glucose cotransporter 2 inhibitors on blood pressure in patients with type 2 diabetes and cardiovascular diseases
    Asanuma, Hiroshi
    HYPERTENSION RESEARCH, 2024, 47 (09) : 2309 - 2311
  • [39] Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Dialysis and Cardiovascular Disease in Patients With Stage 5 Chronic Kidney Disease
    Yen, Fu-Shun
    Hwu, Chii-Min
    Liu, Jia-Sin
    Wu, Yi-Ling
    Chong, Keong
    Hsu, Chih-Cheng
    ANNALS OF INTERNAL MEDICINE, 2024, 177 (06) : 693 - 700
  • [40] A Prospective Study to Evaluate the Effects of Sodium-Glucose Cotransporter 2 Inhibitors in Type 2 Diabetic Patients with Chronic Kidney Disease
    Saldanha, Neil
    Shah, Mita
    Dalal, Monika S.
    Virani, Zaheer Amin
    Parekh, Ishan
    Vora, Hepal
    Rajput, Prashant
    Tapiawala, Shruti
    Shah, Bharat, V
    JOURNAL OF DIABETOLOGY, 2022, 13 (03) : 301 - 304
12345